Current role of cabozantinib in metastatic castration-resistant prostate cancer

References

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. 2008. Int J Cancer 2010;127(12):2893-917
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29
   Google Scholar
• DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. Cancer J Clin 2014;64(4):252-71
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180-92
   PubMed Web of Science ®Google Scholar
• Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008;26(15):2544-9
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, de Wit R, Investigators TAX. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19(10):1749-53
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet 2012;13(10):983-92
   Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424-33
   PubMed Web of Science ®Google Scholar
• Parker C, Sartor O. Radium-223 in prostate cancer. N Engl J Med 2013;369(17):1659-60
   PubMed Web of Science ®Google Scholar
• Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002;1(3):145-52
   Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377(9768):813-22
   PubMed Web of Science ®Google Scholar
• Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncology 2003;10(5):1149-53
   Google Scholar
• Andrea Borghese Apolo YT, Lee M-J, Lee S, et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. J Clin Oncol 2014;32(5s Suppl):abstract 4501
   Google Scholar
• Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16(6):553-72
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhau HE, Osunkoya AO, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 2010;9:9
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12):2298-308
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
   PubMed Web of Science ®Google Scholar
• Nguyen HM, Ruppender N, Zhang X, et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One 2013;8(10):e78881
   PubMed Web of Science ®Google Scholar
• Dai J, Zhang H, Karatsinides A, et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res 2014;20(3):617-30
   PubMed Web of Science ®Google Scholar
• Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Dis 2012;2(3):270-87
   Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15(7):2207-14
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. Clin Cancer Res 2013;31(29):3639-46
   Google Scholar
• Gordon MS VN, Schoffski P, et al. Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J Clin Oncol 2011;29(196s Suppl):abstract3010
   Google Scholar
• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31(4):412-19
   PubMed Web of Science ®Google Scholar
• Smith MR, Sweeney CJ, Corn PG, et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol 2014;32(30):3391-9
   PubMed Web of Science ®Google Scholar
• Basch E, Autio KA, Smith MR, et al. Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. Eur Urol 2014. [Epub ahead of print]
   Google Scholar
• Scher HI SM, Sweeney C, et al. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort. J Clin Oncol 2013;31:abstract 5026
   Google Scholar
• Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29(19):2660-6
   PubMed Web of Science ®Google Scholar
• Lee RJ, Saylor PJ, Michaelson MD, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. J Clin Oncol 2013;19(11):3088-94
   Google Scholar
• Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 1996;93(15):7644-8
   PubMed Web of Science ®Google Scholar
• Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002;60(6):1113-17
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147(2):386-96
   PubMed Web of Science ®Google Scholar
• Street J, Lenehan B. Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism. J Orthop Surg 2009;4:19
   PubMedGoogle Scholar
• Lee RJ, Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J 2013;19(1):90-8
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-59
   PubMed Web of Science ®Google Scholar
• Vuong W, Sartor O, Pal SK. Radium-223 in metastatic castration resistant prostate cancer. Asian J Androl 2014;16(3):348-53
   PubMed Web of Science ®Google Scholar
• Michaelson MD, Oudard S, Ou YC, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 2014;32(2):76-82
   PubMed Web of Science ®Google Scholar
• Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncology 2013;14(8):760-8
   Google Scholar
• Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol 2010;21(2):319-24
   PubMed Web of Science ®Google Scholar
• Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30(13):1534-40
   PubMed Web of Science ®Google Scholar
• A study of cabozantinib (XL184) vs everolimus in subjects with metastatic renal cell carcinoma (METEOR). Available from: https://clinicaltrials.gov/ct2/show/NCT01865747
   Google Scholar
• Study of cabozantinib (XL184) vs placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL). Available from: https://clinicaltrials.gov/ct2/show/NCT01908426?term=NCT01908426&rank=1
   Google Scholar
• A dose escalation study of the safety and pharmacokinetics of GSK1363089 (Formerly XL880) administered orally daily to subjects with solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT00743067?term=GSK1363089&rank=2
   Google Scholar
• A study of E7050 administered orally to patients with advanced solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT00921869?term=NCT00921869&rank=1
   Google Scholar
• Safety study of oral mgcd265 administered without interruption to subjects with advanced malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT00697632?term=NCT00697632&rank=1
   Google Scholar